{'52WeekChange': -0.52408755,
 'SandP52WeekChange': 0.0644362,
 'address1': '3430 East Global Loop',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 0.6577,
 'askSize': 900,
 'averageDailyVolume10Day': 4981950,
 'averageVolume': 5602495,
 'averageVolume10days': 4981950,
 'beta': 1.762464,
 'beta3Year': None,
 'bid': 0.6526,
 'bidSize': 800,
 'bookValue': 0.325,
 'category': None,
 'circulatingSupply': None,
 'city': 'Tucson',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 0.67,
 'dayLow': 0.62,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.309,
 'enterpriseToRevenue': 1.27,
 'enterpriseValue': 23153436,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '520-547-2837',
 'fiftyDayAverage': 0.67062855,
 'fiftyTwoWeekHigh': 1.42,
 'fiftyTwoWeekLow': 0.267,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 48949965,
 'forwardEps': -0.24,
 'forwardPE': -2.7270834,
 'fromCurrency': None,
 'fullTimeEmployees': 108,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.07872,
 'heldPercentInstitutions': 0.58102,
 'industry': 'Diagnostics & Research',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/htgmolecular.com',
 'longBusinessSummary': 'HTG Molecular Diagnostics, Inc. a commercial stage '
                        'life sciences company, focuses on the precision '
                        'medicine. The company offers instrumentation; '
                        'consumables comprising assay kits; and software that '
                        'automate sample processing and profiles various '
                        'molecular targets. Its platforms generate a molecular '
                        'profiling library for detection using next-generation '
                        "sequencing. The company's marketed panels include HTG "
                        'EdgeSeq oncology biomarker panel; HTG EdgeSeq '
                        'immuno-oncology assay; HTG EdgeSeq DLBCL cell of '
                        'origin assay; HTG EdgeSeq path assay; HTG EdgeSeq '
                        'miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL '
                        'cell of origin assay EU; HTG EdgeSeq ALKPlus assay '
                        'EU;HTG EdgeSeq precision immuno-oncology panel; HTG '
                        'lung fusions assay; HTG autoimmune panel; and HTG '
                        'mouse mRNA tumor response panel. It serves '
                        'biopharmaceutical companies, academic research '
                        'centers, and molecular testing laboratories. HTG '
                        'Molecular Diagnostics, Inc. distributes its '
                        'instruments and consumables directly in the United '
                        'States and Europe; and through distributors in parts '
                        'of Europe and internationally. The company has a '
                        'governing agreement with QIAGEN Manchester Limited; '
                        'and an agreement with Illumina, Inc. for the '
                        'development of nuclease-protection-based RNA or DNA '
                        'profiling tests. The company was formerly known as '
                        'HTG, Inc. and changed its name to HTG Molecular '
                        'Diagnostics, Inc. in March 2011. HTG Molecular '
                        'Diagnostics, Inc. was incorporated in 1997 and is '
                        'based in Tucson, Arizona.',
 'longName': 'HTG Molecular Diagnostics, Inc.',
 'market': 'us_market',
 'marketCap': 43912828,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_1519732',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -19384716,
 'nextFiscalYearEnd': 1640908800,
 'open': 0.658,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '877-289-2615',
 'previousClose': 0.7012,
 'priceHint': 4,
 'priceToBook': 2.0138462,
 'priceToSalesTrailing12Months': 2.40928,
 'profitMargins': -1.06354,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 0.67,
 'regularMarketDayLow': 0.62,
 'regularMarketOpen': 0.658,
 'regularMarketPreviousClose': 0.7012,
 'regularMarketPrice': 0.658,
 'regularMarketVolume': 3094086,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 67093700,
 'sharesPercentSharesOut': 0.015700001,
 'sharesShort': 1055163,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 702840,
 'shortName': 'HTG Molecular Diagnostics, Inc.',
 'shortPercentOfFloat': 0.0159,
 'shortRatio': 0.15,
 'startDate': None,
 'state': 'AZ',
 'strikePrice': None,
 'symbol': 'HTGM',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.412,
 'twoHundredDayAverage': 0.5257842,
 'volume': 3094086,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.htgmolecular.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '85706'}